Insider: Ross Bridget A Director - LEMAITRE VASCULAR INC
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 2,916 | 0 | 2,916 |
| Value | $247,072.68 | $0.00 | $247,072.68 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 08/08/2025 | DDS | 2,500 | Direct | COM | $94.00 | $235,000.00 | 2,916 |
| 05/12/2025 | DDS | 3,750 | Direct | COM | $83.20 | $312,000.00 | 2,916 |
| 11/15/2024 | DDS | 3,750 | Direct | COM | $101.47 | $380,512.50 | 2,278 |
| 05/16/2024 | DDS | 5,500 | Direct | COM | $77.99 | $428,945.00 | 2,278 |
| 06/02/2023 | DDS | 5,000 | Direct | COM | $64.24 | $321,200.00 | 1,169 |
| 02/27/2023 | DDS | 7,000 | Direct | COM | $49.27 | $344,890.00 | 1,183 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research